Imatinib mesylate in combination with chemotherapy in four children with de novo and advanced stage Philadelphia chromosome-positive acute lymphoblastic leukemia.
The role of imatinib in childhood Philadelphia chromosome-positive (Ph(+)) acute lymphoblastic leukemia (ALL) has not been established. We treated four children with imatinib in combination with conventional chemotherapy (CT) before stem cell transplantation (SCT). Response evaluation consisted of fluorocytometric analysis of minimal residual disease (MRD) and standard qualitative RT-PCR follow-up.
Fuster
José Luis
JL
Hospital Universitario Virgen de la Arrixaca, Murcia, Spain. josel.fuster@carm.es
Bermúdez
Mar
M
Galera
Ana
A
Llinares
María Esther
ME
Calle
Doris
D
Ortuño
Francisco Jose
FJ
D000971:Antineoplastic Combined Chemotherapy Protocols / Q000008:administration & dosage*; D001549:Benzamides; D002648:Child; D002675:Child, Preschool; D018572:Disease-Free Survival; D005260:Female; D005434:Flow Cytometry; D006801:Humans; D000068877:Imatinib Mesylate; D008297:Male; D009367:Neoplasm Staging; D018365:Neoplasm, Residual; D010879:Piperazines / Q000008:administration & dosage*; D054198:Precursor Cell Lymphoblastic Leukemia-Lymphoma / Q000175:diagnosis / Q000473:pathology / Q000628:therapy*; D011379:Prognosis; D011743:Pyrimidines / Q000008:administration & dosage*; D033581:Stem Cell Transplantation; D014184:Transplantation, Homologous
D001549:Benzamides; D010879:Piperazines; D011743:Pyrimidines; D000068877:Imatinib Mesylate